- Results from a Phase 3 study, IMMhance, assessing AbbVie's (NYSE:ABBV) risankizumab in patients with moderate-to-severe plaque psoriasis met the efficacy endpoints in both phases of the trial.
- In the first phase, 89% of patients receiving risankizumab for 16 weeks achieved at least a 75% improvement in symptoms while 47% achieved totally clear skin, substantially greater than placebo's 8% and 1%, respectively.
- In the second phase, evaluating long-term treatment compared to randomized withdrawal, showed 87% of patients in the risankizumab group who achieved clear or almost clear skin at week 28 maintained their response at week 52 compared to 61% in the withdrawal group.
- No new safety signals were observed.
- The company is moving forward with global regulatory filings.
- Risankizumab selectively binds to interleukin 23 (IL-23), a protein that plays a key role in inflammatory processes associated with a range of chronic immune-mediated diseases. The company licensed the biologic from Boehringer Ingelheim in March 2016.
- Now read: AbbVie Raises Dividend 11%... What Now?
Original article